We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
The investigational next-generation non-nucleoside reverse transcriptase inhibitor lersivirine controls HIV as well as standard-care efavirenz (Sustiva) in treatment-naive patients, researchers said. MedPage Today
